The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ... Patients with beta-thalassemia major (also known as Cooley's anemia) have a reduction or absence of beta protein in their hemoglobin, resulting in severe anemia, which requires regular blood ...
Medically reviewed by Gagandeep Brar, MD Key Takeaways Beta thalassemia minor is a blood disorder that can cause mild anemia, but it often doesn't show symptoms.If both parents carry the trait for ... Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ... Seeking Alpha: U.S.
thalassemia anemia, FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia Nasdaq: AGIO Rises Nearly 20% On FDA Approval Of AQVESME For Thalassemia Anemia AGIO Rises Nearly 20% On FDA Approval Of AQVESME For Thalassemia Anemia Seeking Alpha: Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
